Drugs / GRNOPC1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01217008 | Oct 2010 → Jul 2013 | spinal cord injury | Lineage Cell Therapeutics, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2011-10-20 | Geron Corporation | Results Geron Presents Clinical Data Update from GRNOPC1 Spinal Cord Injury Trial geron.com ↗
To date, GRNOPC1 has been well tolerated with no serious adverse events. |
| 2011-06-07 | Geron Corporation | Results Geron Presents Data From GRNOPC1 Trial at International Conferences on Spinal Cord Medicine and Rehabilitation geron.com ↗
Data on the first two patients were presented at the 2011 International Conference on Spinal Cord Medicine and Rehabilitation in Washington, D.C. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2011-10-20 | Geron Corporation | Geron Presents Clinical Data Update from GRNOPC1 Spinal Cord Injury Trial geron.com ↗ |
| 2011-06-07 | Geron Corporation | Geron Presents Data From GRNOPC1 Trial at International Conferences on Spinal Cord Medicine and Rehabilitation geron.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GRNOPC1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01217008 ↗ |
| Modality | Cell therapy | “One injection of 2 million GRNOPC1 cells.” NCT01217008 ↗ |